Home › Trials › NCT06486428

Community engagement to eliminate disparities in small-cell lung cancer

A Study to Evaluate a Remote, Decentralized, Direct-to-Patient Strategy for Clinical Research Engagement of Patients With Small Cell Lung Cancer (SCLC).

Addario Lung Cancer Medical Institute · NCT06486428

This project will see if a remote, direct-to-patient approach can improve outreach and biospecimen collection for people with extensive-stage or transformed small-cell lung cancer.

Quick facts

Study typeObservational
Enrollment30 (estimated)
Ages18 Years and up
SexAll
SponsorAddario Lung Cancer Medical Institute (other)
Locations52 sites (Multiple Locations, Alabama and 51 other locations)
Trial IDNCT06486428 on ClinicalTrials.gov

What this trial studies

This non-interventional, single coordinating-center study tests a decentralized, direct-to-patient model for remote biospecimen (blood) collection and survey-based data gathering in adults with small-cell lung cancer. Enrollment is coordinated by the Addario Lung Cancer Medical Institute via a study webpage or phone hotline, with informed consent obtained remotely and medical records used to confirm diagnosis and treatment history. Participants complete a baseline and three-month follow-up questionnaire about diagnosis, treatment history, factors impacting care, quality of life, and preferences for accessing novel therapies. The study is focused on feasibility and improving patient engagement rather than on delivering therapeutic interventions.

Who should consider this trial

Good fit: Adults (≥18) in the U.S. who read and speak English, can provide informed consent, are willing to share clinical records and complete remote surveys, and have extensive-stage primary SCLC or transformed SCLC (tSCLC).

Not a fit: People who cannot communicate in English, cannot complete remote consent or sample collection, have uncontrolled medical or psychiatric conditions that limit participation, or are not U.S.-based may not benefit from this decentralized approach.

Why it matters

Potential benefit: If successful, this approach could make it easier for more people with SCLC to participate in research and contribute biospecimens, improving representation and accelerating biomarker and therapeutic research.

How similar studies have performed: Decentralized, direct-to-patient biospecimen collection has shown promise in other cancer and rare-disease programs, but it is relatively novel and less tested specifically for small-cell lung cancer.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Men or women greater than or equal to 18 years of age at the time of consent
2. Ability to read, write and communicate in English
3. Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF)
4. Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required
5. Willing to comply with the requirements of the study
6. Diagnosis of extensive stage primary SCLC or tSCLC

Exclusion Criteria:

1. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements
2. Subjects who previously enrolled to this study

Note: Concurrent enrollment in other clinical trials is NOT exclusionary

Where this trial is running

Multiple Locations, Alabama and 51 other locations

+2 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Small-cell Lung Cancer, SCLC, Lung Cancer

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.